Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Study in Healthy Subjects and in Patients With Stable Impaired Renal Function to Assess the Effect of Severe Renal Impairment on Licarbazepine Pharmacokinetics and Metabolism After the Single Administration of a 500 mg Licarbazepine Immediate Release (IR) Tablet

NCT00426036 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT00426036
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00426036 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Study in Healthy Subjects and in Patients With Stable Impaired Renal Function to Assess the Effect of Severe Renal Impairment on Licarbazepine Pharmacokinetics and Metabolism After the Single Administration of a 500 mg Licarbazepine Immediate Release (IR) Tablet
Lead sponsor
Novartis
Phase
Phase 1
Overall status
Completed
Start date
June 30, 2006
Completion date
Not reported
Enrollment
12
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy